Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin.
Jones
Robin L
RL
Department of Medicine, Royal Marsden Hospital, London, UK. robin.jones@rmh.nthames.nhs.uk
Berry
Gerald J
GJ
Rubens
Robert D
RD
Miles
David W
DW
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D044584:Carcinoma, Ductal / Q000188:drug therapy* / Q000556:secondary; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D008854:Microscopy, Electron; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology / Q000648:ultrastructure; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000556:secondary; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000556:secondary; D013160:Splenic Neoplasms / Q000188:drug therapy / Q000556:secondary; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin